SYMPLICITY HTN-3: what should be the impact on clinical practice?

With the collaboration of the Resistant Hypertension Course

Chairpersons: T.F. Lüscher, F. Mahfoud
Evaluator: A. Spencer

Learning Objectives

  • To discover the most recent data around devices targeting the autonomic nervous system to treat cardiovascular conditions

Presentations available when logged in:

  • What was known before this trial: evidence and guidelines
  • Trial review: the data, the statistics, the conclusions
  • Yes - SYMPLICITY HTN-3 will definitely impact my clinical practice
  • No - SYMPLICITY HTN-3 will not impact my clinical practice
  • Differences between randomised, controlled trials and real-word experience
  • Catheter-based renal denervation systems - One size does not fit all!